Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial reveals that Letrozole is superior to Clomiphen in ov induction and rediucing miscarraige rate

 

The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial  compared CC with Letrozole  and results were duly presented at American Society for Reproductive Medicine (ASRM) 2013 clearly showed that as compared to clomiphene, ovulation rate, cumulative pregnancy rate and live birth rate is  better for letrozole in patients with PCOS, and it is not associated with increased risk of pregnancy loss, multiple pregnancies or adverse effects on fetus.[2]Subsequently, a review by Roque M et al affirmed the superiority of letrozole over clomiphene in PCOS patients. [3]

 

A 2014 Cochranedatabase systemic review also concluded “Letrozole improves live birth and pregnancy rates in subfertile women with anovulatory PCOS, compared to clomiphene citrate, though the evidence is low.”  [4]

 &  

 

 

---

[1] Biljan MM, Hemmings R, Brassard N, et al. The outcome of 150 babies following treatment with letrozole or letrozole and gonadotropins. Presented at the American Society for Reproductive Medicine 61st Annual Meeting; October 14-19, 2005; Montreal, Quebec. Abstract O-231. References 

[2] https://www.ncbi.nlm.nih.gov/pubmed/22265923

[3] https://www.ncbi.nlm.nih.gov/pubmed/26479460

[4] https://www.ncbi.nlm.nih.gov/pubmed/24563180

Posted by anjali vyas at 1:22:00 AM